{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:52:56Z","timestamp":1769003576522,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tunisian Ministry of Higher Education and Scientific Research","award":["LBME19CBS02"],"award-info":[{"award-number":["LBME19CBS02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11472-z","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:33:42Z","timestamp":1768905222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients"],"prefix":"10.1007","volume":"53","author":[{"given":"Rania","family":"Abdelmaksoud-Dammak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihel","family":"Ammous-Boukhris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slim","family":"Charfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrine","family":"Kallel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Khemakhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameni","family":"Feki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahya Sellami","family":"Boudawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhem","family":"Yangui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afef","family":"Khanfir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja Mokdad","family":"Gargouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"11472_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"7689","key":"11472_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non\u2013small cell lung cancer. Nature 553(7689):446\u2013454","journal-title":"Nature"},{"key":"11472_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela Cruz CS (2020) Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1\u201324","journal-title":"Clin Chest Med"},{"issue":"6","key":"11472_CR4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMc2313463","volume":"390","author":"M Reck","year":"2024","unstructured":"Reck M, Remon J, Hellmann MD (2024) First-line immunotherapy for non\u2013small-cell lung cancer. N Engl J Med 390(6):573\u2013586","journal-title":"N Engl J Med"},{"key":"11472_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R et al (2021) Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci 22:792","journal-title":"Int J Mol Sci"},{"key":"11472_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","volume":"4","author":"JL Schneider","year":"2023","unstructured":"Schneider JL, Lin JJ, Shaw AT (2023) ALK-positive lung cancer: a moving target. Nat Cancer 4:330\u2013343","journal-title":"Nat Cancer"},{"key":"11472_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32:1101\u20131110","journal-title":"Ann Oncol"},{"key":"11472_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.08.007","volume":"193","author":"S Yoda","year":"2019","unstructured":"Yoda S, Dagogo-Jack I, Hata AN (2019) Targeting oncogenic drivers in lung cancer: recent progress, current challenges and future opportunities. Pharmacol Ther 193:20\u201330","journal-title":"Pharmacol Ther"},{"issue":"2","key":"11472_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N (2011) New driver mutations in non\u2013small-cell lung cancer. Lancet Oncol 12(2):175\u2013180","journal-title":"Lancet Oncol"},{"key":"11472_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167\u2013179","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"11472_CR11","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res 5(9):2892\u20132911","journal-title":"Am J Cancer Res"},{"key":"11472_CR12","volume":"12","author":"LM Boustany","year":"2022","unstructured":"Boustany LM, Hilal L, Kattan J, Nasr R, Mukherji D (2022) Molecular profile of lung cancer in the Middle East and North Africa region. Front Oncol 12:871504","journal-title":"Front Oncol"},{"issue":"8","key":"11472_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/genes13081499","volume":"13","author":"R Abdelmaksoud-Dammak","year":"2022","unstructured":"Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R et al (2022) Predominance of the rare EGFR mutation p.L861Q in Tunisian patients with non-small cell lung carcinoma. Genes (Basel) 13(8):1499","journal-title":"Genes (Basel)"},{"key":"11472_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060514","volume":"8","author":"D Dhieb","year":"2019","unstructured":"Dhieb D, Belguith I, Capelli L, Chiadini E, Canale M, Bravaccini S et al (2019) Analysis of genetic alterations in Tunisian patients with lung adenocarcinoma. Cells 8:514","journal-title":"Cells"},{"issue":"1","key":"11472_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12890-018-0706-5","volume":"18","author":"Z Mraihi","year":"2018","unstructured":"Mraihi Z, Ben Amar J, Bouacha H, Rammeh S, Hila L (2018) EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry. BMC Pulm Med 18(1):132","journal-title":"BMC Pulm Med"},{"issue":"3","key":"11472_CR16","first-page":"65","volume":"66","author":"A Arfaoui Toumi","year":"2018","unstructured":"Arfaoui Toumi A, Blel A, Aloui R, Zaibi H, Ksentinini M, Boudaya MS et al (2018) Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma. Curr Res Transl Med 66(3):65\u201370","journal-title":"Curr Res Transl Med"},{"issue":"5676","key":"11472_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497\u2013500","journal-title":"Science"},{"issue":"25","key":"11472_CR18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"2","key":"11472_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213\u201322","journal-title":"Lancet Oncol"},{"key":"11472_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.lungcan.2014.06.011","volume":"85","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z, Han JQ (2014) EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis. Lung Cancer 85:339\u2013345","journal-title":"Lung Cancer"},{"issue":"6","key":"11472_CR21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B et al (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21(6):560\u20132","journal-title":"Nat Med"},{"issue":"6","key":"11472_CR22","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG et al (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17(6):1616\u20131622","journal-title":"Clin Cancer Res"},{"issue":"2","key":"11472_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125","journal-title":"N Engl J Med"},{"issue":"1","key":"11472_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350","journal-title":"N Engl J Med"},{"issue":"5","key":"11472_CR25","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.21037\/jtd.2019.08.30","volume":"12","author":"C Lazzari","year":"2020","unstructured":"Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M (2020) Mechanisms of resistance to osimertinib. J Thorac Dis 12(5):2851\u20132858","journal-title":"J Thorac Dis"},{"issue":"12","key":"11472_CR26","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","volume":"49","author":"CM Blakely","year":"2017","unstructured":"Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE et al (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49(12):1693\u20131704","journal-title":"Nat Genet"},{"issue":"10","key":"11472_CR27","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F et al (2021) Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 16(10):1647\u20131662","journal-title":"J Thorac Oncol"},{"key":"11472_CR28","doi-asserted-by":"publisher","first-page":"1366260","DOI":"10.3389\/fimmu.2024.1366260","volume":"15","author":"Y Xiang","year":"2024","unstructured":"Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L et al (2024) Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Front Immunol 15:1366260","journal-title":"Front Immunol"},{"issue":"3","key":"11472_CR29","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S1470-2045(24)00008-1","volume":"25","author":"SM Lim","year":"2024","unstructured":"Lim SM, Syn NL, Cho BC (2024) Combined EGFR and MET inhibition in EGFR-mutated non\u2013small-cell lung cancer. Lancet Oncol 25(3):e92\u2013e104","journal-title":"Lancet Oncol"},{"issue":"6","key":"11472_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298721","volume":"19","author":"S Boukansa","year":"2024","unstructured":"Boukansa S, Mouhrach I, El Agy F, El Bardai S, Bouguenouch L, Serraj M et al (2024) Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: a first report. PLoS One 19(6):e0298721","journal-title":"PLoS One"},{"issue":"3","key":"11472_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.36401\/JIPO-24-35","volume":"8","author":"A AlJassim","year":"2025","unstructured":"AlJassim A, Kanbour A, Azribi F, AlNassar M, Mohsen R, Dawod S et al (2025) Prevalence of molecular mutations in non-small cell lung cancer and current treatment approaches in the MENA region: systematic review and expert opinion. J Immunother Precis Oncol 8(3):233\u2013241","journal-title":"J Immunother Precis Oncol"},{"issue":"1","key":"11472_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-018-4774-y","volume":"18","author":"Z Benbrahim","year":"2018","unstructured":"Benbrahim Z, Antonia T, Mellas N (2018) EGFR mutation frequency in middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC Cancer 18(1):891","journal-title":"BMC Cancer"},{"issue":"1","key":"11472_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2021","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J et al (2021) Worldwide prevalence of epidermal growth factor receptor mutations in Non-Small cell lung cancer: A Meta-Analysis. Mol Diagn Ther 26(1):7\u201318","journal-title":"Mol Diagn Ther"},{"issue":"12","key":"11472_CR34","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1097\/JTO.0b013e3181f38816","volume":"5","author":"YH Choi","year":"2010","unstructured":"Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH et al (2010) Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol 5(12):1949\u201352","journal-title":"J Thorac Oncol"},{"issue":"75","key":"11472_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26","journal-title":"Sci Transl Med"},{"issue":"10","key":"11472_CR36","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jtho.2024.06.008","volume":"19","author":"RA Soo","year":"2024","unstructured":"Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF et al (2024) Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study. J Thorac Oncol 19(10):1449\u20131459","journal-title":"J Thorac Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11472-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T23:01:42Z","timestamp":1768950102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11472"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11472-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from The Faculty of Medicine of Sfax, Tunisia (CPP SUD N\u00b0 0277\/2022), and written informed consent was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"303"}}